Justin Hasenkamp

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

Peter Dreger, Hartmut Döhner, Matthias Ritgen et al. · Blood · 2010 · 304 citations · Full text

Medicine, Immunology, Oncology +15

Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial

Justin Hasenkamp, Gerald Wulf, Peter Dreger et al. · The Lancet Oncology · 2014 · 109 citations

Medicine, Immunology, Oncology +16

Treatment of invasive fungal diseases in cancer patients—Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

Markus Ruhnke, Oliver A. Cornely, Martin Schmidt‐Hieber et al. · Mycoses · 2020 · 72 citations · Full text

Medicine, Infectious Diseases, Oncology +17

Gene transfer into human T lymphocytes and natural killer cells by Ad5/F35 chimeric adenoviral vectors

Roland Schroers, York Hildebrandt, Justin Hasenkamp et al. · Experimental Hematology · 2004 · 57 citations

Life Sciences, Immunology, Molecular Biology +17

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Gerald Illerhaus, Andrés J.M. Ferreri, Mascha Binder et al. · Blood · 2022 · 44 citations · Full text

Medicine, Oncology, Chemotherapy +14